Journal: Cancer discovery
The report describes results from the pivotal phase III EPCORE LF-1 trial in relapsed/refractory follicular lymphoma, a setting where treatment options beyond immunochemotherapy are limited and rituximab–lenalidomide (R²) is essentially the only established alternative.
- Comparison: Adding the bispecific antibody epcoritamab to R² (epcoritamab + R²) was compared with R² alone.
- Key finding: The three-drug regimen substantially improved outcomes, reducing the risk of disease progression or death by 79% relative to R².
- Implication: This positions epcoritamab + R² as a potentially more effective option than R² alone for patients with relapsed or refractory follicular lymphoma, pending full clinical data, longer follow-up, and regulatory decisions.